Exact Sciences Corp ((EXAS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

WASHINGTON (dpa-AFX) - Exact Sciences Corp. (EXAS) announced the U.S. launch of CancerguardT, its multi-cancer early detection or MCED blood test, now available as a laboratory-developed test or LDT.

Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations "Exact Sciences’ research at ACG 2025 ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Exact Sciences Corp is currently ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data being presented at the American College of Gastroenterology (ACG) Annual ...

Christina Majaski writes and edits finance, credit cards, and travel content. She has 14+ years of experience with print and digital publications. Khadija Khartit is a strategy, investment, and ...